~~<i id='7B283E58D0'><strike id='7B283E58D0'><tt id='7B283E58D0'><pre id='7B283E58D0'></pre></tt></strike></i>~~

Home» Wikipedia» comprehensive

comprehensive

author：hotspot 2025-10-01 14:01:42 Page View：453

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Gene therapy’s promise and the high cost of hope
Next article： Medical records are filled with copy

focus

DIEP, the 'gold standard' of breast reconstruction, is under threat

AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

Live blog: Hearing on CRISPR

AdobeTheFoodandDrugAdministrationisconveningameetingofoutsideexpertsonTuesdaytoreviewexa-cel,aCRISPR

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

All of Us, NIH's precision medicine initiative, gets a big boost

AdobeOverthepastfiveyears,twouniquefederaleffortshavecollectedthehealthrecordsofmillionsofAmericans.

WSS

comprehensive

comprehensive

explore

focus

All of Us, NIH's precision medicine initiative, gets a big boost